Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
The firm placed 45 of its T2Dx diagnostics instruments in 2019, but plans to reduce that number in 2020 to focus on instrument utilization.
The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.
Invitae reported $66.3 million in revenues for the fourth quarter, which fell short of the consensus Wall Street estimate of $68.1 million.
The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.
For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.
The firm saw low-single digit growth across its business segments in the quarter as well as in the full year.
Diagnostics revenues for the fourth quarter were $1.76 billion, up 4 percent from $1.69 billion in the same quarter last year.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.